MAY 1·Stock Titan▲
Praxis (NASDAQ: PRAX) details 2026 virtual meeting, director slate and Say-on-Pay
Praxis Precision Medicines, Inc. is holding its 2026 virtual annual meeting on June 10, 2026, where stockholders will vote on the election of three Class III directors, the ratification of Ernst & Young LLP as auditor, and an advisory Say-on-Pay resolution regarding executive compensation. The company reported a 283% one-year return for stockholders in 2025, driven by significant clinical, regulatory, and capital-raising milestones. Praxis has also evolved its executive compensation program for 2026 to include performance-based restricted stock units (PSUs) to further align executive incentives with company performance and long-term value creation.
APR 29·Simply Wall Street▲
How Investors May Respond To Praxis (PRAX) Securing Dual FDA Reviews For Key Neurology Drug Candidates
Praxis Precision Medicines (PRAX) has achieved two significant FDA milestones: Priority Review for relutrigine in pediatric epilepsy, with a PDUFA date in September 2026, and acceptance of the NDA for ulixacaltamide in essential tremor, with a PDUFA date in January 2027. These developments suggest Praxis is evolving into a multi-asset regulatory pipeline company. Despite ongoing losses and dilution risk, these catalysts are expected to sharpen the focus on successful approvals and potentially lead to a substantial upside in its stock price.
